007460.KS
Aprogen Medicines Inc. [007460.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
007460.KS Stock Summary
Top 10 Correlated ETFs
007460.KS
Top 10 Correlated Stocks
007460.KS
In the News
007460.KS Financial details
Company Rating
Buy
Market Cap
354.75B
Income
-77.7B
Revenue
137.99B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
367
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-2.96
Forward P/E
-
PEG
-0.24
P/S
2.57
P/B
1.31
P/C
-
P/FCF
-2.56
Quick Ratio
-
Current Ratio
2.88
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-483.92
EPS next Y
-
EPS next Q
-
EPS this Y
167.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.8%
Revenue last 5Y
8.95%
Revenue Q/Q
-3.04%
EPS Q/Q
-27.19%
-
-
-
-
SMA20
7.82%
SMA50
-7.06%
SMA100
-18.32%
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
-35%
ROC
-0.16%
Gross Margin
17%
Oper. Margin
-61%
Profit Margin
-56%
Payout
-
Shs Outstand
252.67M
Shs Float
92.42M
-
-
-
-
Target Price
-
52W Range
1207.0-6328.7344
52W High
-77.81%
52W Low
+16.32%
RSI
52.41
Rel Volume
0.53
Avg Volume
2.04M
Volume
1.09M
Perf Week
4.15%
Perf Month
10.12%
Perf Quarter
-36.31%
Perf Half Y
-29.4%
-
-
-
-
Beta
0.60797
-
-
Volatility
59.26%, 66.1%
Prev Close
0.86%
Price
1404
Change
-1.89%
007460.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1K | 1.71K | 2.25K | 2.44K | 389.43 | |
| Net income per share | -631.71 | 400.63 | -577.5 | -215.97 | -576.99 | |
| Operating cash flow per share | -29.3 | -24.39 | 398.34 | -148.68 | -564.1 | |
| Free cash flow per share | -108.77 | -203.15 | 343.17 | -185.21 | -687.46 | |
| Cash per share | 2.36K | 3.82K | 4.2K | 2.76K | 235.89 | |
| Book value per share | 3.85K | 5.89K | 5.64K | 5.8K | 1.07K | |
| Tangible book value per share | 3.84K | 11.23K | 12.13K | 12.12K | 2.22K | |
| Share holders equity per share | 3.85K | 5.89K | 5.64K | 5.8K | 1.07K | |
| Interest debt per share | 3.74K | 2.06K | 1.61K | 1.56K | 497.55 | |
| Market cap | 1175.4B | 373.87B | 346.98B | 292.52B | 115.08B | |
| Enterprise value | 1284.95B | 387.15B | 336.02B | 309.12B | 162.21B | |
| P/E ratio | -36.61 | 20.4 | -10.62 | -23.4 | -0.99 | |
| Price to sales ratio | 23.03 | 4.78 | 2.73 | 2.07 | 1.47 | |
| POCF ratio | -789.27 | -335.11 | 15.4 | -33.99 | -1.01 | |
| PFCF ratio | -212.61 | -40.23 | 17.87 | -27.29 | -0.83 | |
| P/B Ratio | 6.01 | 1.39 | 1.09 | 0.87 | 0.54 | |
| PTB ratio | 6.01 | 1.39 | 1.09 | 0.87 | 0.54 | |
| EV to sales | 25.17 | 4.95 | 2.64 | 2.19 | 2.07 | |
| Enterprise value over EBITDA | -199.18 | 8.66 | 33.83 | -48.3 | -2.49 | |
| EV to operating cash flow | -862.83 | -347.02 | 14.91 | -35.92 | -1.43 | |
| EV to free cash flow | -232.43 | -41.66 | 17.31 | -28.84 | -1.17 | |
| Earnings yield | -0.03 | 0.05 | -0.09 | -0.04 | -1.01 | |
| Free cash flow yield | 0 | -0.02 | 0.06 | -0.04 | -1.2 | |
| Debt to equity | 0.87 | 0.32 | 0.27 | 0.24 | 0.42 | |
| Debt to assets | 0.43 | 0.13 | 0.1 | 0.1 | 0.15 | |
| Net debt to EBITDA | -16.98 | 0.3 | -1.1 | -2.59 | -0.72 | |
| Current ratio | 1.42 | 3.19 | 5.11 | 4.37 | 2.35 | |
| Interest coverage | 0.08 | 4.53 | 1.08 | -0.23 | -11.54 | |
| Income quality | 0.05 | -0.06 | -0.69 | 0.69 | 0.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.03 | 0.03 | 0.03 | 0.37 | |
| Research and developement to revenue | 0.09 | 0.02 | 0.01 | 0.01 | 0.49 | |
| Intangibles to total assets | 0 | 0.01 | 0 | 0 | 0.02 | |
| Capex to operating cash flow | 2.71 | 7.33 | -0.14 | 0.25 | 0.22 | |
| Capex to revenue | -0.08 | -0.1 | -0.02 | -0.01 | -0.32 | |
| Capex to depreciation | -1.99 | -2.52 | -0.72 | -0.5 | -0.87 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.01 | |
| Graham number | 7.39K | 7.29K | 8.56K | 5.31K | 3.73K | |
| ROIC | 0.01 | 0.09 | 0.01 | -0.01 | -0.23 | |
| Return on tangible assets | -0.08 | 0.03 | -0.04 | -0.02 | -0.2 | |
| Graham Net | -1.52K | 1.18K | 1.8K | 872.65 | -301.5 | |
| Working capital | 41.51B | 238.45B | 349.41B | 373.57B | 121.64B | |
| Tangible asset value | 195.42B | 513.89B | 686.3B | 701.3B | 447.58B | |
| Net current asset value | -58.31B | 217.47B | 290.24B | 364.58B | 72.73B | |
| Invested capital | 0.87 | 0.32 | 0.27 | 0.24 | 0.42 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.55B | 824.36M | 1.55B | 1.65B | 3.02B | |
| Average inventory | 4.79B | 11.29B | 17.35B | 19.1B | 41.18B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 10.22 | 5.72 | 6.16 | 21.16 | |
| Days of inventory on hand | 45.2 | 107.86 | 68.14 | 69.35 | 310.76 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 35.72 | 63.76 | 59.27 | 17.25 | |
| Inventory turnover | 8.07 | 3.38 | 5.36 | 5.26 | 1.17 | |
| ROE | -0.16 | 0.07 | -0.1 | -0.04 | -0.54 | |
| Capex per share | -79.47 | -178.76 | -55.17 | -36.52 | -123.36 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 624.8 | 530.92 | 125.64 | 184.31 | 0 | |
| Net income per share | 3.37 | -132.27 | -93.58 | -149.34 | 0 | |
| Operating cash flow per share | -10.1 | 327.91 | -509.78 | -116.91 | 0 | |
| Free cash flow per share | -19.09 | 321.85 | -595.51 | -141.28 | 0 | |
| Cash per share | 1.83K | 1.53K | 272.41 | 235.89 | 0 | |
| Book value per share | 5.09K | 5.49K | 530.31 | 1.07K | 0 | |
| Tangible book value per share | 10.54K | 10.71K | 2.16K | 2.22K | 0 | |
| Share holders equity per share | 5.09K | 5.49K | 530.31 | 1.07K | 0 | |
| Interest debt per share | 1.17K | 335.19 | 377.64 | 460.23 | 0 | |
| Market cap | 306.98B | 360.06B | 631.08B | 115.08B | 0 | |
| Enterprise value | 337.07B | 276.22B | 655.97B | 162.21B | 0 | |
| P/E ratio | 339.25 | -9.69 | -7.65 | -0.96 | 0 | |
| Price to sales ratio | 7.32 | 9.66 | 22.8 | 3.1 | 0 | |
| POCF ratio | -452.88 | 15.64 | -5.62 | -4.89 | 0 | |
| PFCF ratio | -239.65 | 15.94 | -4.81 | -4.05 | 0 | |
| P/B Ratio | 0.9 | 0.93 | 5.4 | 0.54 | 0 | |
| PTB ratio | 0.9 | 0.93 | 5.4 | 0.54 | 0 | |
| EV to sales | 8.04 | 7.41 | 23.7 | 4.37 | 0 | |
| Enterprise value over EBITDA | -186.14 | -78.05 | -31.24 | -12.93 | 0 | |
| EV to operating cash flow | -497.27 | 12 | -5.84 | -6.9 | 0 | |
| EV to free cash flow | -263.14 | 12.22 | -5 | -5.71 | 0 | |
| Earnings yield | 0 | -0.03 | -0.03 | -0.26 | 0 | |
| Free cash flow yield | 0 | 0.06 | -0.21 | -0.25 | 0 | |
| Debt to equity | 0.22 | 0.05 | 0.68 | 0.42 | 0 | |
| Debt to assets | 0.09 | 0.03 | 0.13 | 0.15 | 0 | |
| Net debt to EBITDA | -16.61 | 23.69 | -1.19 | -3.76 | 0 | |
| Current ratio | 5.04 | 13.61 | 3 | 2.35 | 2.88 | |
| Interest coverage | 0 | -0.67 | -10.94 | -10.32 | -2.09 | |
| Income quality | -3 | -2.48 | 1.46 | 0.78 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 1.72 | 0.19 | 0.74 | |
| Research and developement to revenue | 0.01 | 0.03 | 0 | 0.05 | 0 | |
| Intangibles to total assets | 0 | 0 | 0.02 | 0.02 | 0 | |
| Capex to operating cash flow | 0.89 | -0.02 | 0.17 | 0.21 | 0 | |
| Capex to revenue | -0.01 | -0.01 | -0.68 | -0.13 | 0 | |
| Capex to depreciation | -0.66 | -0.46 | -0.98 | -0.67 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | -0.01 | 0 | |
| Graham number | 621.04 | 4.04K | 1.06K | 1.9K | 0 | |
| ROIC | 0 | 0 | -0.08 | -0.05 | -0.03 | |
| Return on tangible assets | 0 | -0.01 | -0.03 | -0.05 | -0.03 | |
| Graham Net | 334.76 | 1.05K | -148.3 | -301.5 | 0 | |
| Working capital | 410.16B | 463.11B | 148.01B | 121.64B | 134.98B | |
| Tangible asset value | 707.48B | 751.86B | 476.68B | 447.58B | 455.79B | |
| Net current asset value | 399.43B | 453.67B | 99.27B | 72.73B | 71.16B | |
| Invested capital | 0.22 | 0.05 | 0.68 | 0.42 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.01B | 2.37B | 3.87B | 4.68B | 2.09B | |
| Average inventory | 22.3B | 24.33B | 42.46B | 60.71B | 30.73B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 6.01 | 7.75 | 22.86 | 9.84 | 0 | |
| Days of inventory on hand | 66 | 75.1 | 265.19 | 144.57 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 14.97 | 11.61 | 3.94 | 9.14 | 0 | |
| Inventory turnover | 1.36 | 1.2 | 0.34 | 0.62 | 0 | |
| ROE | 0 | -0.02 | -0.18 | -0.14 | -0.1 | |
| Capex per share | -8.99 | -6.06 | -85.73 | -24.37 | 0 |
007460.KS Frequently Asked Questions
What is Aprogen Medicines Inc. stock symbol ?
Aprogen Medicines Inc. is a KR stock and trading under the symbol 007460.KS
What is Aprogen Medicines Inc. stock quote today ?
Aprogen Medicines Inc. stock price is $1404 today.
Is Aprogen Medicines Inc. stock public?
Yes, Aprogen Medicines Inc. is a publicly traded company.
Company Profile
- Volume Average 2.04M
- Market Capitalization 354.75B
- Employee 367
- CEO Ki-Cheol Lim
- Headquarters Seongnam-si,KR
- IPO Date 2005-09-29
-
Website
https://www.aprogen-kic.com 
Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs. In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment building working safely in the pressurized water reactor power plant; foamglas, a cellular glass insulation product; and fireproof insulation works in the POSCO furnaces and boilers. The company was formerly known as Aprogen KIC Inc. and changed its name to Aprogen Medicines Inc. April 2021. Aprogen Medicines Inc. was founded in 1971 and is based in Seongnam-si, South Korea.
